Primary antiphospholipid syndrome in pediatrics: New criteria, new opportunities
Authors' conclusion
The 2023 ACR/EULAR APS criteria improve the classification of pediatric patients by including non-thrombotic criteria; however, there are other non-thrombotic manifestations that are common in children that should be taken into account in this population.
Study context
- Population
- Patients <18 years with primary APS by 2023 ACR/EULAR classification criteria, General Hospital of the National Medical Center La Raza, Mexico, January 2013 to January 202522 female, 18 male
- Participants
- 40 patients
- Outcome
- Clinical, laboratory and treatment characteristics
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
- Mean age at diagnosis (years)
- 12.8
- Time to diagnosis (weeks)
- 15.4
- Thrombosis
- 14
- Thrombocytopenia
- 34
- Autoimmune hemolytic anemia
- 18
- Fisher Evans syndrome
- 17
- Livedo
- 33
- Skin ulcers
- 2
- Raynaud's phenomenon
- 15
- Epileptic seizures
- 2
- Chorea
- 1
- Renal involvement
- 4
- Prolonged aPTT
- 39 (97.5%)
- Positive LA
- 39
- Positive aCL IgG
- 32
- Positive aCL IgM
- 18
- Anti-B2GPI IgG positive (of 17 tested)
- 15
- Anti-B2GPI IgM positive (of 12 tested)
- 4
- Anticoagulation
- 13
- Antiplatelet agents
- 29
- Steroids
- 35
- Immunosuppressants
- 33
- RTX
- 6
Observational data: associations, not effects.
Further findings
Death from alveolar hemorrhage
- Deaths
- 1
Original publication
Primary antiphospholipid syndrome in pediatrics: New criteria, new opportunities. Lupus. Published 12 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →